News articles about Abbott Laboratories (NYSE:ABT) have been trending somewhat negative on Friday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Abbott Laboratories earned a news impact score of -0.03 on Accern’s scale. Accern also assigned news articles about the healthcare product maker an impact score of 45.8029930083081 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment’s analysis:

Abbott Laboratories (ABT) traded up $0.24 during trading hours on Friday, hitting $59.31. The stock had a trading volume of 7,362,958 shares, compared to its average volume of 6,410,000. Abbott Laboratories has a fifty-two week low of $39.25 and a fifty-two week high of $59.68. The company has a market capitalization of $103,240.00, a P/E ratio of 49.02, a price-to-earnings-growth ratio of 1.88 and a beta of 1.55. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The business had revenue of $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. During the same period last year, the company earned $0.59 earnings per share. The business’s revenue for the quarter was up 28.8% compared to the same quarter last year. analysts forecast that Abbott Laboratories will post 2.5 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 1.89%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Thursday, January 11th. Abbott Laboratories’s dividend payout ratio (DPR) is 92.56%.

A number of analysts recently issued reports on ABT shares. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Friday, September 22nd. Cowen restated a “buy” rating on shares of Abbott Laboratories in a research report on Sunday, September 24th. Wells Fargo & Co raised their price target on Abbott Laboratories from $57.00 to $64.00 and gave the stock an “outperform” rating in a research report on Thursday, September 28th. Barclays raised their price target on Abbott Laboratories from $57.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, September 28th. Finally, BMO Capital Markets restated a “hold” rating and issued a $53.00 price target on shares of Abbott Laboratories in a research report on Monday, October 2nd. Six research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $60.24.

In related news, insider Daniel Gesua Sive Salvadori sold 28,319 shares of Abbott Laboratories stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $54.92, for a total value of $1,555,279.48. Following the completion of the sale, the insider now directly owns 102,117 shares in the company, valued at $5,608,265.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alejandro D. Wellisch sold 2,153 shares of Abbott Laboratories stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $55.86, for a total value of $120,266.58. Following the completion of the sale, the insider now owns 10,256 shares of the company’s stock, valued at $572,900.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 501,172 shares of company stock valued at $27,533,150. Corporate insiders own 0.76% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Abbott Laboratories (ABT) Getting Somewhat Negative News Coverage, Study Finds” was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.watchlistnews.com/abbott-laboratories-abt-getting-somewhat-negative-news-coverage-study-finds/1814526.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.